Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1466

Shown on this page

Current sort

Stored official records

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Biospecimen Collection, Echocardiography, Magnetic Resonance Imaging, Mammography, Multigated Acquisition Scan, Pertuzumab, Questionnaire Administration, Trastuzumab (Herceptin), Ultrasound; Procedure · Biological · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Early Parkinson Disease (Early PD), Idiopathic Parkinson Disease, Parkinson, Parkinson Disease, Parkinson Disease, Idiopathic
Interventions: NEU-411, Placebo; Drug · Other
Lead sponsor: Neuron23 Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Personalized cardiac pacing; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 26
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more

Conditions: Advanced or Metastatic Solid Tumor
Interventions: PLN-101095, Pembrolizumab; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more

Conditions: Acute Kidney Injury, Coronary Artery Disease, Delirium, Heart Valve Disease, Ischemic Stroke
Interventions: CardioGard Embolic Protection Cannula, Standard Aortic Cannula; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 842 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more

Conditions: Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Colonoscopy, Computed Tomography, Esophagogastroduodenoscopy, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Questionnaire Administration, Rituximab, Zanubrutinib; Procedure · Other · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 60 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 238
States / cities: Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more

Conditions: Metastatic Colorectal Adenocarcinoma, Oligometastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Microwave Ablation, Positron Emission Tomography, Resection, Stereotactic Ablative Radiotherapy; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 188
States / cities: Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 146 more

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 409
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more

Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Cyclophosphamide, Doxorubicin, Duvelisib, Etoposide, Oral azacitidine, Prednisone, Vincristine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 96
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Lenvatinib, Pembrolizumab, Pembrolizumab/Quavonlimab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Myelofibrosis
Interventions: Momelotinib, Nusivertib, Ruxolitinib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more

Conditions: Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
Interventions: Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Peposertib; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 46
States / cities: Duarte, California • Irvine, California • La Jolla, California + 34 more

About this Emory University (Winship Cancer Institute) institution page

What this page lists: ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Emory University (Winship Cancer Institute)

Filter and sort this campus

Stored official records

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

ELEVATE-HFpEF Clinical Study

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

CTSN Embolic Protection Trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

About this Emory University (Winship Cancer Institute) institution page